|drug1085||Famotidine 20 MG Wiki||0.71|
|drug3324||lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate Wiki||0.71|
|D003141||Communicable Diseases NIH||0.06|
|D018352||Coronavirus Infections NIH||0.03|
There are 2 clinical trials
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.
Description: virus negative conversion rate in second week, overall virus negative conversion rateMeasure: Virus negative conversion rate Time: 14-20 days
Description: defined as: the rate of Axillary temperature ≤37.5 ℃ for at least 48hMeasure: Antipyretic rate Time: 14-20 days
Description: time to relieve symptoms of fever, cough, dyspnea, myalgia, etcMeasure: Symptom relief time Time: 14-20 days
Description: no adjuvant oxygen therapy, resting oxygen saturation＞95%, oxygenation index＞350Measure: Finger oxygen improvement rate Time: 14-20 days
Description: Mild, common type progression to severe or critical illness rateMeasure: Disease progression rate Time: 14-20 days
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global. As the COVID-19 is an emerging infectious disease, it has not scientifically recognized and has no effective drugs for treatment currently. Therefore, we will launch a scientific project "The efficacy and safety of carrimycin treatment in 520 patients with COVID-19 stratificated clinically: A multicenter, randomized (1:1), open-controlled (one of lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish the criteria for clinical cure and the early predictive model of COVID-19 progression. The primary efficiency outcomes were:(1) Fever to normal time (day); (2) Pulmonary inflammation resolution time (HRCT) (day); and (3)Negative conversion (%) of SARS-CoV-2 RNA at the end of treatment. The secondary efficiency outcomes and adverse events were observed.
Description: Fever to normal time (day)Measure: Fever to normal time (day) Time: 30 days
Description: Pulmonary inflammation resolution time (HRCT) (day)Measure: Pulmonary inflammation resolution time (HRCT) (day) Time: 30 days
Description: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatmentMeasure: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment Time: 30 days